

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./



Form PTO-1449 4-2008 U.S. Department of Commerce Patent and Trademark Office		INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						Atty. Docket No. 60390-IA/JPW/GJG/ML	Serial No. 10/718,280				
						Applicants: Arlindo L. Castelhano et al.							
						Filing Date November 20, 2003		Group 1624					
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
	1	5	2	9	6	4	8	4	3/22/94	Coghlan et al.			
	2	5	6	4	6	1	3	0	7/8/97	Shi			
	3	5	8	7	7	1	8	0	3/2/99	Linden et al.			
	4	5	8	8	9	0	2	6	3/30/99	Alanine et al.			
	5	5	9	3	5	9	6	4	8/10/99	Baraldi et al.			
	6	6	1	1	7	8	7	8	9/12/00	Linden			
	7	6	4	6	5	4	5	6	10/15/02	Springer et al.			
	8	6	9	1	6	8	0	4	7/12/05	Castelhano et al.			
	9	7	2	0	2	2	5	2	4/10/07	Wilson et al.			
	10	20	03	01	39	4	2	7	11/1/05	Castelhano et al.			
	11	20	03	02	29	0	6	7	12/11/03	Castelhano et al.			
	12	20	05	01	19	2	7	1	6/2/05	Castelhano et al.			
	13	20	04	00	82	5	9	9	4/29/04	Castelhano et al.			
	14	20	05	00	43	3	3	2	2/24/05	Castelhano et al.			
	15	20	08	00	70	9	3	6	3/20/08	Castelhano et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number						Date	Country	Class	Subclass	Translation	
												Yes	No
	16	9	7	4	7	6	0	1	12/18/97	PCT			
	17	9	9	6	4	4	0	7	12/16/99	PCT			
	18	9	9	0	8	4	6	0	2/18/99	PCT			
	19	0	0	0	3	7	4	1	1/27/00	PCT			
	20	20	03	05	3	3	6	1	7/3/03	PCT			
	21	20	03	05	3	3	6	6	7/3/03	PCT			
	22	0	7	2	9	7	5	8	9/4/96	EPO			
	23	1	2	4	6	6	2	3	8/9/06	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)												
25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)												
26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)												
27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)												
28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)												
29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", Ann. NY. Acad. Sci., 825: 11-22												
30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" J. Neuroscience 20(15) : 5848-5852												
31	Avila, M. Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" J. of Pharmacol. 241-245												
32	Baraldi, P.G. et al. (1996) "Pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" J. Med. Chem. 39: 1164-1171												
33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", Tips, 21: 456-459												
34	Baraldi P., et al. "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", Curr. Pharm. Design 8: 2299-2332, 2002												
EXAMINER	/Alton Pryor/			DATE CONSIDERED		10/20/2008							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Applicants: Arlindo Castelhano et al.  
Serial No.: 10/718,280  
Filed: November 20, 2003  
Exhibit A

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office								Atty. Docket No. 60390-IA/JPW/GJC/ML		Serial No. 10/718,280		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Applicants: Arlindo L. Castelhano et al.				
										Filing Date November 20, 2003		Group 1624		
<b>U.S. PATENT DOCUMENTS</b>														
Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate	
	1	5	2	9	6	4	8	4	3/22/94	Coghlan et al.				
	2	5	6	4	6	1	3	0	7/8/97	Shi				
	3	5	8	7	7	1	8	0	3/2/99	Linden et al.				
	4	5	8	8	9	0	2	6	3/30/99	Alanine et al.				
	5	5	9	3	5	9	6	4	8/10/99	Baraldi et al.				
	6	6	1	1	7	8	7	8	9/12/00	Linden				
	7	6	4	6	5	4	5	6	10/15/02	Springer et al.				
	8	6	9	1	6	8	0	4	7/12/05	Castelhano et al.				
	9	7	2	0	2	2	5	2	4/10/07	Wilson et al.				
	10	20	03	01	39	4	2	7	11/1/05	Castelhano et al.				
	11	20	03	02	29	0	6	7	12/11/03	Castelhano et al.				
	12	20	05	01	19	2	7	1	6/2/05	Castelhano et al.				
	13	20	04	00	82	5	9	9	4/29/04	Castelhano et al.				
	14	20	05	00	43	3	3	2	2/24/05	Castelhano et al.				
	15	11	9	0	3	1	4	7	9/20/07	Castelhano et al.				
<b>FOREIGN PATENT DOCUMENTS</b>														
		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
	16	9	7	4	7	6	0	1	12/18/97	PCT				
	17	9	9	6	4	4	0	7	12/16/99	PCT				
	18	9	9	0	8	4	6	0	2/18/99	PCT				
	19	0	0	0	3	7	4	1	1/27/00	PCT				
	20	20	03	05	3	3	6	1	7/3/03	PCT				
	21	20	03	05	3	3	6	6	7/3/03	PCT				
	22	0	7	2	9	7	5	8	9/4/96	EPO				
	23	1	2	4	6	6	2	3	8/9/06	EPO				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)													
25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)													
26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)													
27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)													
28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)													
29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", Ann. NY. Acad. Sci., 825: 11-22													
30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" J. Neuroscience 20(15) : 5848-5852													
31	Avila, M.Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" J. of Pharmacol. 241-245													
32	Baraldi, P.G. et al. (1996) "Pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" J. Med. Chem. 39: 1164-1171													
33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", Tips, 21: 456-459													
34	Baraldi P., et al. "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", Curr. Pharm. Design 8: 2299-2332, 2002													
EXAMINER		/Alton Pryor/		DATE CONSIDERED		10/20/2008								
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office  INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Atty. Docket No. 60390-IA/JPW/GJC/ML	Serial No. 10/718,280	
				Applicants: Arlindo Castelhano et al.		
				Filing Date November 20, 2003	Group 1624	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>						
	Document Number	Date	Country	Class	Subclass	Translation
						Yes      No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
35	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." <i>Expert Opinion on Therapeutic Patents</i> , 9(5):515-527					
36	Baraldi, P.G. et al., (2004) "Allosteric modulators for the A1 adenosine receptor." <i>Expert Opinion on Therapeutic Patents</i> , 14(1):71-79					
37	Baraldi, P.G. (2003) "Recent developments in the field of A2A and A3 adenosine receptor antagonists" <i>Eur. J. Med. Chem.</i> 38(4) 367					
38	Blazynski C., (1990) "Discrete Distributions of Adenosine Receptors in Mammalian Retina", <i>Journal of Neurochemistry</i> , 53: 648-655					
39	Borman, S. (2001) "A3 Receptors" <i>C&amp;EN</i> , 79(7), 37					
40	Braas K.M., et al., (1987) "Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina", <i>Proceedings of the National Academy of Science</i> , 84: 3906-3910					
41	Bradford M. M., (1976) "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", <i>Anal. Biochem.</i> , 72: 248					
42	Bremer et al. (2002) "Therapy of Crohn's Disease in Childhood", <i>Expert Opin. Pharmacother.</i> 3(7): 809-825					
43	Broach, J. R. et al., (1983) "Vectors for high level, inducible expression of cloned genes in yeast", Inouye (ed.), <i>Experimental Manipulation of Gene Expression</i> . Academic Press, New York, 83-117					
44	Casavola V., et al., (1983) "Adenosine A3 receptor activation increases cytosolic calcium concentration via calcium influx in A6 cells", <i>Drug Development Research</i> , 43 (1): 62					
45	Cheng, Y. and Prusoff, W. H. (1973) "Relationship Between The Inhibition Constant (Ki) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition (I50) Of An Enzymatic Reaction", <i>Biochem. Pharmacol.</i> , 22: 3099-3109					
46	Christianson, T. W. et al., (1992) "Multifunctional yeast high-copy-number shuttle vectors", <i>Gene</i> , 110: 119-122					
47	Christofi, F. L. et al. (2001), "Differential Gene Expression of Adenosine A1, A2a, A2b, and A3 Receptors in the Human Enteric Nervous System", <i>J. Comp. Neurol.</i> 439(1): 46-64					
48	Coney, A. M. et al. (1998) "Role of Adenosine and its Receptors in the Vasodilation Induced in the Cerebral Cortex of the Rat by Systemic Hypoxia" <i>J. Physiol.</i> 509: 507-518					
49	Cooper, J. A. (1995) "Adenosine Receptor-induced Cyclic AMP Generation and Inhibition of 5-hydroxytryptamine release in Human Platelets" <i>Br. J. Clin. Pharmacol.</i> 40:43-50					
50	Corset, V. et al. (2000), "Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor", <i>Nature</i> , 407 (6805): 747-750					
51	Dubey, R. K. et al. (2001), "A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts", <i>Hypertension</i> 37: 716-721					
52	Duzic, E. et al. (1992) "Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-binding Protein-coupled Receptors", <i>J. Biol. Chem.</i> , 267: 9844-9851					
53	Ezeamuzie C., et al. (1999), <i>British Journal of Pharmacology</i> , 127: 188-194					
54	Faivre, K. et al., (2001) "Suppression of Cellular Invasion by Activated G-Protein Subunits Gαo, Gαi1, and Gαi3 and Sequestration of Gβγ", <i>Mol. Pharmacol.</i> 60: 363-372					
55	Feoktistov, I. and Biaggioni, I., (1997) "Adenosine A2B Receptors", <i>Pharmacol. Rev.</i> 49(4): 381-402					
EXAMINER	/Alton Pryor/	DATE CONSIDERED	10/20/2008			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-IA/JPW/GJG/ML		Serial No. 10/718,280	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo Castelhano et al.			
				Filing Date November 20, 2003		Group 1624	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>							
	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
56	Feoktistov, I. et al., (2002) "Differential Expression of Adenosine Receptors in Human Endothelial Cells", <i>Circulation Research</i> 90: 531-538						
57	Fishman P (2003) "Pharmacology and therapeutic applications of A3 receptor subtype" <i>Curr. Top. Med. Chem.</i> 3(4): 463-9						
58	Fozard J., et al., (1996) "Mast cell degranulation following adenosine A3 receptor activation in rats", <i>European Journal of Pharmacology</i> , 298: 293-297						
59	Franco M., et al., (1999) "Adenosine Regulates Renal Nitric Oxide Production in Hypothyroid Rats", <i>Journal of the American Society of Nephrology</i> , 1681-1688						
60	Gao, Z. et al., "A2B Adenosine and P2Y2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells" <i>J. Bio. Chem.</i> (1999) 274(9): 5972-5980						
61	Ghiardi, G. J. et al. (1999) "The Purine Nucleoside Adenosine in Retinal Ischemia-Reperfusion Injury" <i>Vision Research</i> 39:2519-2535						
62	GenBank accession # S46950						
63	GenBank accession numbers S45235 and S56143						
64	Grant, M.B. et al., (2001) "Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2B Adenosine Receptor Stimulation", <i>Invest. Ophthalmol. Vis. Sci.</i> 42(9): 2068-2073						
65	Guerra L., et al., (1998) "Adenosine A3 receptor activation increases cytosolic calcium influx in A6 cells", <i>Nephrology Dialysis Transplantation</i> , 13 (6): A5						
66	Guo, Y. et al., (2001) "Targeted deletion of A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning." <i>J Mol Cell Cardiol</i> , 33:825-830						
67	Haynes, J. Jr. et al., (1999) "5-(N-ethylcarboxamido) adenosine desensitizes the A2b-adenosine receptor in lung circulation", <i>Am. J. Physiol.</i> 276(6): H1877-H1883						
68	Herndon, J.L. et al., (1992) Herndon, J.L. et al., "Ketanserin Analogs: Structure-Affinity Relationships for 5-HT2 and 5-HT1C Serotonin Receptor Binding", <i>J. Med. Chem.</i> 35(26): 4903-4910						
69	Hoeschst India Ltd., India "Pharmacologically active pyrimido "[4,5-b]indoles and their salts." Database accession No. 106:84629 HCA XP002121648						
70	Kanda, T. et al. (1998) "Adenosine A2a Receptors Modify Motor Function in MPTP-treated Common Marmosets" <i>Neuroreport</i> 9: 2857-2860						
71	Kanda, T. et al. (2000) "Combined Use of the Adenosine A2a Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but not Dyskinesia in MPTP-Treated Monkeys" <i>Experimental Neurology</i> 162: 321-327						
72	Kang, Y. et al., (1990) "Effects of Expression of Mammalian G $\alpha$ and Hybrid Mammalian-Yeast G $\alpha$ Proteins on the Yeast Pheromone Response Signal Transduction Pathway", <i>Mol. Cell. Biol.</i> , 10: 2582-2590						
73	Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" <i>Chem. Abstracts</i> 56:8713						
EXAMINER /Alton Pryor/		DATE CONSIDERED 10/20/2008					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-IA/JPW/GJG/ML	Serial No. 10/718,280		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo Castelhano et al.			
				Filing Date November 20, 2003	Group 1624		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes      No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
74		Kiritsy, J.A. et al., (1978) "Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrifamycin SV N-(4-Substituted phenyl) piperazinoacethydrazones" <i>J. Med. Chem.</i> 21(12): 1301-1307					
75		Klumpp, D.A. et al., (1999) "Synthesis of Aryl-Substituted Piperidines by Superacid Activation of Piperidones" <i>J. Org. Chem.</i> 64(18): 6702-6705					
76		Knutsen, L.J.S. et al. (2001) <i>Curr. Opin. Invest. Drugs</i> 2(5):668-673					
77		Kopf, S.R. et al. (1999) "Adenosine and Memory Storage: Effect of A1 and A2 Receptor Antagonists" <i>Psychopharmacology</i> 146:214-219					
78		Li, J.M. et al. (1998) "Adenosine A2a Receptors Increase Arterial Endothelial Cell Nitric Oxide" <i>J. Surg. Res.</i> 80:357-364					
79		Linden, J. et al., (1998) "The Structure and Function of A1 and A2B Adenosine Receptors" <i>Life Sciences</i> 62(17-18): 1519-1524					
80		Meade et al., PubMed Abstract ( <i>Life Sci.</i> 69(11):1225-40) August 2001					
81		Mitchell, C.H. et al., "Adenosine A3 Receptor Activation Reduces Cell Volume and Activates Cl <sup>-</sup> Current in Human Ciliary Epithelial Cells", <i>FASEB J.</i> A134 (Abstract only)					
82		Michell, C.H. (1999) "A3 adenosine receptors regulate Cl-channels of nonpigmented ciliary epithelial cells" <i>Am. J. Physiol.</i> 276: C659-C666					
83		Mirabet, M. et al., (1999) "Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation" <i>J. Cell. Sci.</i> 112(4): 491-502					
84		Montesinos, M.C. et al. (2002) "Adenosine Promotes Wounds Healings and Mediates Angiogenesis in Response to Tissue Injury Via Occupancy of A2a Receptors" <i>American Journal of Pathology</i> 160(6):2009-2018					
85		Müller, C.E. et al., "Imidazo [2,1-i] purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A2A- and A3-Adenosine Receptor Antagonists", (2002) <i>J. Med. Chem.</i> 45(16): 3440-3450					
86		Müller, C.E. (2001) "A3 Adenosine Receptor Antagonists" Mini Reviews in Med. Chem. 1(4): 339					
87		Nagarathnam, D. et al., (1998) "Design and Synthesis of Novel α1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", <i>J. Med. Chem.</i> 41(26): 5320-5333					
88		Nishiyama, A. et al. (2001) "Interactions of Adenosine A1 and A2 a Receptors on Renal Microvascular Reactivity" <i>Am. J. Physiol. Renal Physiol.</i> 280:F406-F414					
EXAMINER		/Alton Pryor/		DATE CONSIDERED		10/20/2008	
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-IA/JPW/GJG/ML		Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelbano et al.		
					Filing Date November 20, 2003		Group 1624
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes      No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
89	Ohana G., et al., (2001) "Differential Effect of Adenosine on Tumor and Normal Cell Growth: Focus on the A3 Adenosine Receptor", <i>Journal of Cellular Physiology</i> , 186: 19-23						
90	Phillips, J.W. (1995) "The Effects of Selective A1 and A2a Adenosine Receptor Antagonists on Cerebral Ischemic Injury in the Gerbil"						
91	Polosa (2002) "Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease", <i>Eur. Respir. Journal</i> 20,488-496						
92	Priego, E.-M. et al., "Pyrido [2,1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent Human A3 Adenosine Receptor Antagonists", (2002) <i>J. Med. Chem.</i> , 45(16): 3337-3344						
93	Ralevic, V. And Burnstock, G., (1998) "Receptors for Purines and Pyrimidines", <i>Pharmacol. Rev.</i> 50(3): 413-492						
94	Regnault, K. et al., (2002) "G-protein $\alpha$ olf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells", <i>Oncogene</i> 21(25): 4020-4031						
95	Regulation of Downstream Effectors By GPCRs, (1999) <i>FASEB J.</i> , Abstracts 147.1-147.6						
96	Reshkin J., et al., (2000) "Activation of A3 Adenosine Receptor Induces Calcium Entry and Chloride Secretion in A6 Cells", <i>J. Membrane Biol.</i> , 178: 103-113						
97	Robinson, "Medical Therapy of Inflammatory Bowel Disease for the 21st Century", <i>Eur J Surg. Suppl</i> 582:90-98, 1998						
98	Sawynok J., et al., (1997) "Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine", <i>European Journal of Pharmacology</i> , 333: 1-7						
99	Shiozaki, S. et al. (1999) "Actions of Adenosine A2a Receptor Antagonist KW-6002 on Drug-induced Catalepsy and hypokinesia Caused by Reserpine or MPTP" <i>Psychopharmacology</i> 147:90-95						
100	Simone, Oncology: Introduction Cecil Textbook of Medicine, 20th Edition, Vol. 1, pp. 1004-1010, 1996						
101	Singh et al., "Immune therapy in inflammatory bowel disease and models of colitis", <i>British Journal of Surgery</i> , 88: 1558-1569, 2001						
102	Strohmeier, G. R. et al., (1995) "The A2b Adenosine Receptor Mediates cAMP Responses to Adenosine Receptor Agonists in Human Intestinal Epithelia", <i>J. Bio. Chem.</i> , 270: 2387-2394						
103	Svenningsson, P. et al. (1999) "Distribution, Biochemistry and Function of Striatal Adenosine A2a Receptors" <i>Prog. Neurobiol.</i> 59(4):355-396						
104	Tanaka, H. et al. "Preparation and formulation of fused pyrimidine compounds as CRF receptor antagonists." Database accession no. 129:109098 HCA XP002121647						
105	Taomoto, M. et al. (2000) "Localization of Adenosine A2 Receptor in Retinal Development and Oxygen-Induced Retinopathy" <i>Investigative Ophthalmology &amp; Visual Science</i> 41(1):230-243						
106	Van Niel, M.B. et al., "Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT <sub>2</sub> D Receptor Ligands with Improved Pharmacokinetic Profiles" <i>J. Med. Chem.</i> (1999) 42(12): 2087-2104						
107	Varani, K. et al. (1998) "[ <sup>3</sup> H]-SCH 58261 Labelling of Functional A2a Adenosine Receptors in Human Neutrophil Membranes" <i>Br. J. Pharmacol.</i> 123:1723-1731						
EXAMINER <i>/Alton Pryor/</i>		DATE CONSIDERED <i>10/20/2008</i>					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Applicants:</b> Arlindo Castelbano et al.			
				Filing Date November 20, 2003		Group 1624	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes      No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
108	Von Lubitz D., et al., (1999) "Stimulation of Adenosine A3 Receptors in Cerebral Ischemia", <u>Ann. NY Acad. Sci.</u> , 890: 93-106						
109	Von Lubitz, D., et al., (1999) "Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects", <u>European Journal of Pharmacology</u> , 367: 157-163						
110	West, R.A. et al. (1961) "2-alkyl(aryl)-and 2,7-dimethyl-4-substituted aminopyrrolo[2,3-d]pyrimidines." <u>J. Org. Chem.</u> , 26:3809-3812						
111	Yan, Luo et al. (2003) Expert Opinion on Emerging Drugs, vol. 8, no. 2 pp. 537-576						
112	Yao Y., et al., (1997) "Adenosine A3 Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3 Antagonists", <u>Biochemical And Biophysical Research Communications</u> , 232: 317-322						
113	Zhao Z., et al., (2000) "A role for the A3 Adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice", <u>Biochimica et Biophysica Acta</u> , 1500: 280-290						
114	International Search Report issued in PCT International Application No. PCT/US99/12135, filed June 1, 1999						
115	International Search Report issued in PCT International Application No. PCT/US00/32702, filed December 1, 2000						
116	International Search Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
117	International Search Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
118	International Search Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
119	International Search Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
120	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US99/121358						
121	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US00/32702						
122	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
123	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
124	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
125	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
126	Supplemental European Search Report; for EP Application No. 02 80 5676; issued 2/7/2005						
127	Partial European Search Report for EP Application No. 06 01 6543.8; completed 10/4/2006						
128	Partial European Search Report; for EP Application No. 01 99 7029; completed 12/21/2004						
EXAMINER	/Alton Pryor/		DATE CONSIDERED 10/20/2008				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office					Atty. Docket No. 60390-1A/JPW/GJG/NDP	Serial No. 10/718,280
		INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhano et al.	
							Filing Date November 20, 2003	Group
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
/A.P./		10 4 9 7 4 5 1	5/27/04	Castelhano et al.				
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
EXAMINER		/Alton Pryor/	DATE CONSIDERED		10/20/2008			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Applicants: Arlindo L. Castelhano et al.  
 Serial No.: 10/718,280  
 Filed: November 20, 2003  
**Exhibit A**